Sahlgrenska University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2022

  1. 2021 ESC/EACTS Guidelines for the management of valvular heart disease

    European Heart Journal, Vol. 43, Núm. 7, pp. 561-632

2018

  1. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

    European Heart Journal, Vol. 39, Núm. 14, pp. 1131-1143

  2. New prospects for PCSK9 inhibition?

    European heart journal

2017

  1. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk

    European Heart Journal, Vol. 38, Núm. 29, pp. 2245-2255

2011

  1. Generic and therapeutic substitution: A viewpoint on achieving best practice in Europe

    British Journal of Clinical Pharmacology